The Predictive Value of Semi-quantitative Index of99mTc-3PRGD2 SPECT/CTfor Patients with HER2 Positive Breast Cancer

被引：0
|
作者：
Liu, Haiyan [1 ]
Li, Wanting [1 ]
Cui, Yongping [4 ]
Qin, Lijun [1 ,5 ]
Wu, Zhifang [1 ,3 ]
Ren, Yuan [5 ]
Liu, Jing [2 ]
Zhang, Guochen [6 ]
Hu, Guang [1 ,3 ]
Wang, Hongliang [1 ,3 ]
Cui, Yali [1 ]
Niu, Jing [1 ]
Li, Sijin [1 ,3 ]
机构：
[1] Shanxi Med Univ, Hosp 1, Taiyuan, Shanxi, Peoples R China
[2] Shanxi Med Univ, Hosp 1, Dept Gen Surg, Taiyuan, Shanxi, Peoples R China
[3] Shanxi Med Univ, Mol Imaging Precis Med Collaborat Innovat, Taiyuan, Shanxi, Peoples R China
[4] Shanxi Med Univ, Translat Med Res Ctr, Taiyuan, Shanxi, Peoples R China
[5] Shanxi Med Univ, Tumor Hosp, Taiyuan, Shanxi, Peoples R China
[6] Shanxi Med Univ, Tumor Hosp, Dept Breast Surg, Taiyuan, Shanxi, Peoples R China
来源：
JOURNAL OF NUCLEAR MEDICINE | 2018年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1367
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Preparation, evaluation, and SPECT/CT imaging of 99mTc-radiolabeled nanobody for Her2-positive breast cancer
    Song, Hongjie
    Lian, Weiling
    Shi, Qin
    Wang, Ming-Wei
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2019, 62 : S467 - S467
  • [32] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [33] Predictive Biomarker of Response to Neoadjuvant Therapy in HER2 Positive Breast Cancer
    Zhao, Jing
    Meisel, Jane
    Suo, Aili
    Zhang, Chao
    Wei, Zhimin
    Aneja, Ritu
    Li, Zaibo
    Nahta, Rita
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2019, 99
  • [34] MAF1 is a predictive biomarker in HER2 positive breast cancer
    Cabarcas-Petroski, Stephanie
    Olshefsky, Gabriella
    Schramm, Laura
    PLOS ONE, 2023, 18 (10):
  • [35] HER2-Targeted Affibody Molecule 99mTc-ABH2 for Imaging HER2 Expression in Breast Cancer
    Jin, Xiaona
    Zhang, Yuwei
    Cao, Xi
    Wang, Peipei
    Ren, Chao
    Cai, Jiong
    Wang, Xuefei
    Jing, Hongli
    Sun, Qiang
    Li, Fang
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (01) : 25 - 30
  • [36] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Horimoto, Yoshiya
    Ishizuka, Yumiko
    Ueki, Yuko
    Higuchi, Toru
    Arakawa, Atsushi
    Saito, Mitsue
    BMC CANCER, 2022, 22 (01)
  • [37] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Yoshiya Horimoto
    Yumiko Ishizuka
    Yuko Ueki
    Toru Higuchi
    Atsushi Arakawa
    Mitsue Saito
    BMC Cancer, 22
  • [38] Development of a 99mTc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer
    Zhao, Lingzhou
    Liu, Changcun
    Xing, Yan
    He, Jin
    O'Doherty, Jim
    Huang, Wenhua
    Zhao, Jinhua
    MOLECULAR PHARMACEUTICS, 2021, 18 (09) : 3616 - 3622
  • [39] Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting
    Wu, Ziping
    Xu, Shuguang
    Zhou, Liheng
    Yin, Wenjin
    Lin, Yanpin
    Du, Yueyao
    Wang, Yaohui
    Jiang, Yiwei
    Yin, Kai
    Zhang, Jie
    Lu, Jinsong
    ONCOTARGETS AND THERAPY, 2018, 11 : 801 - 808
  • [40] HER2 mutation status in Japanese HER2-positive breast cancer patients
    Yumi Endo
    Yu Dong
    Naoto Kondo
    Nobuyasu Yoshimoto
    Tomoko Asano
    Yukari Hato
    Mayumi Nishimoto
    Hiroyuki Kato
    Satoru Takahashi
    Ryoichi Nakanishi
    Tatsuya Toyama
    Breast Cancer, 2016, 23 : 902 - 907
12345